Meeting
2021 ASCO Annual Meeting
A phase I trial evaluating NBTXR3 activated by radiotherapy in combination with nivolumab or pembrolizumab in patients with advanced cancers.
Authors
Colette Shen
University of North Carolina at Chapel Hill, Chapel Hill, NC
Colette Shen , Jessica M. Frakes , Jiaxin Niu , Ari Rosenberg , Jared Weiss , Jimmy J. Caudell , Katherine LaRoque Jameson , Patricia Said , Tanguy Y. Seiwert
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
PD1/PD-L1 Inhibitor Combinations
Clinical Trial Registration Number
NCT03589339
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 2590)
DOI
10.1200/JCO.2021.39.15_suppl.2590
Abstract #
2590
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Efficacy from the ongoing phase I trial Study 1100 with NBTXR3 activated by radiotherapy in combination with nivolumab or pembrolizumab in patients with locoregionally recurrent or metastatic HNSCC.
First Author: Colette Shen
Poster
2024 ASCO Annual Meeting
Early signs of efficacy in patients with anti-PD-1 naïve and anti-PD-1 resistant HNSCC treated with NBTXR3/SBRT in combination with nivolumab or pembrolizumab in the phase I trial Study 1100.
First Author: Colette Shen
Poster
2020 ASCO Virtual Scientific Program
Phase I study of NBTXR3 activated by radiotherapy in patients with advanced cancers treated with an anti-PD-1 therapy.
First Author: Colette Shen
Poster
2023 ASCO Annual Meeting
Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: An AGEO European Cohort.
First Author: Lorenzo Pilla